secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001193125-23-241316
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea regains Nasdaq compliance, enters WuXi Biologics deals, details CFO separation
--------------------------------------------------------------------------------

- Regained Nasdaq minimum bid price compliance after 1-for-25 reverse stock split effective Sept 8, 2023.
- Novated WuXi Biologics MSA for SPY001 program; term through June 2027 or completion of work orders.
- Entered cell line license agreement with WuXi Biologics; $150k license fee plus potential single-digit royalty on third-party manufactured sales.
- Former CFO Jonathan Alspaugh severance: $623k cash, $168k retention bonus, $500/hr consulting fee through Feb 2024, and accelerated option vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523241316/0001193125-23-241316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523241316/d519116d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-241316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer